J&J: studies the potential of nipocalamib in anemia

(CercleFinance.com) - Johnson & Johnson presented the results of several studies on warm autoimmune hemolytic anemia (wAIHA) at the 2024 annual meeting of the American Society of Hematology.


Affecting around one in 8,000 people, this rare and serious disease leads to premature destruction of red blood cells causing fatigue, shortness of breath and other severe symptoms up to and including loss of consciousness.

The laboratory reports widespread dissatisfaction with current treatment options, due to their side effects and lack of efficacy.

We are excited about the potential of our ongoing clinical program with nipocalimab for this condition and look forward to sharing the results of our Phase 2/3 study next year, it said.


Copyright (c) 2024 CercleFinance.com. All rights reserved.